Cancer Genetics, Inc. (CGIX:NASDAQ) Investor Relations Material

Overview

Cancer Genetics is a precision and translational medicine company that offers proprietary preclinical test systems through its vivoPharm subsidiary. These test systems are highly valued by the pharmaceutical industry, biotech companies, and academic research centers in the early stages of clinical diagnostics. The company's focus is on driving drug discovery and developing novel therapies. vivoPharm conducts tailored studies guiding drug development from compound libraries to in vitro and in vivo data to support Investigational New Drug filings. The subsidiary operates in AAALAC accredited and GLP compliant audited facilities.

Frequently Asked Questions

What is Cancer Genetics, Inc.'s ticker?

Cancer Genetics, Inc.'s ticker is CGIX

What exchange is Cancer Genetics, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Cancer Genetics, Inc.'s headquarters?

They are based in Rutherford, New Jersey

How many employees does Cancer Genetics, Inc. have?

There are 51-200 employees working at Cancer Genetics, Inc.

What is Cancer Genetics, Inc.'s website?

It is https://www.cancergenetics.com/

What type of sector is Cancer Genetics, Inc.?

Cancer Genetics, Inc. is in the Healthcare sector

What type of industry is Cancer Genetics, Inc.?

Cancer Genetics, Inc. is in the Biotechnology industry

Who are Cancer Genetics, Inc.'s peers and competitors?

The following five companies are Cancer Genetics, Inc.'s industry peers:

- VIVUS, Inc

- Compugen Ltd.

- Arix Bioscience

- China Biologic Products, Inc.

- Akari Therapeutics Plc